Table 3.
Efficacy analysis.
Patient populatin | |
---|---|
n = 33 | |
PFS (median/months) (95% CI) | 11 (7.8–14.1)) |
Tumor response | |
Complete response | 4 (%12) |
Partial response | 2 (%6) |
Stable disease | 10 (%30) |
Progressive disease | 15 (%45) |
Mixed response | 2 (%6) |
OS (median/months) (95% CI) | 21 (10.6–31.3) |
PFS, progression free survival; OS, overall survival; CI, confidence interval